Drugs / MYM-V101
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01084343 Comparator | Nov 2009 → Sep 2010 | — | Mymetics Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYM-V101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01084343 ↗ |
| Modality | Vaccine | “Participants received placebo or MYM-V101 vaccine at 10 μg/dose or 50 μg/dose intramuscularly at week 0 and 8, and intranasally at week 16 and 24.” PMID 23437055 ↗ Feb 2013 |
| Route | Intramuscular | “MYM-V101 was safe and well-tolerated at both doses administered by the intramuscular and intranasal routes” PMID 23437055 ↗ Feb 2013 |
| Route | Intranasal | “MYM-V101 was safe and well-tolerated at both doses administered by the intramuscular and intranasal routes” PMID 23437055 ↗ Feb 2013 |